EBS Emergent BioSolutions Inc.

Emergent BioSolutions Announces Addition to Russell 3000® Index

Emergent BioSolutions Announces Addition to Russell 3000® Index

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market , effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes.

“Inclusion in the Russell 3000® Index is an important milestone in Emergent’s ongoing transformation,” said Joe Papa, president and chief executive officer of Emergent BioSolutions. “This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our commitment to strong execution, financial stability, and long-term value creation for our shareholders.”

The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Wednesday, April 30, 2025, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, is automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, approximately $10.5 trillion in assets are benchmarked against the Russell U.S. indexes, which belong to FTSE Russell, a prominent global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, visit the “Russell Reconstitution” section on the .

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our  and follow us on , , ,  and . 

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding utilization of the company’s share repurchase program, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Trademarks and logos are the property of their respective owners.

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

Media Contact:

Assal Hellmer

Vice President, Communications



EN
20/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE

Emergent BioSolutions Secures $17 Million Contract Modification for Or...

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension...

 PRESS RELEASE

Emergent BioSolutions Receives New Contract Modification for ACAM2000®...

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancil...

 PRESS RELEASE

Emergent BioSolutions Awarded $30 Million Contract Modification for CY...

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed...

 PRESS RELEASE

Emergent BioSolutions Underscores Continued Support of Increasing Nalo...

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's “Campus Surge” initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of Inter...

 PRESS RELEASE

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link One-on-one meetings HCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link One-on-one meetings Please contact your conference representative to request one-on-one meetings. Participa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch